Reporter nanoparticle that monitors its anticancer efficacy in real time
Abstract
The ability to identify responders and nonresponders very early during chemotherapy by direct visualization of the activity of the anticancer treatment and to switch, if necessary, to a regimen that is effective can have a significant effect on the outcome as well as quality of life. Current approaches to quantify response rely on imaging techniques that fail to detect very early responses. In the case of immunotherapy, the early anatomical readout is often discordant with the biological response. This study describes a self-reporting nanomedicine that not only delivers chemotherapy or immunotherapy to the tumor but also reports back on its efficacy in real time, thereby identifying responders and nonresponders early on.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 29, 2016
- Source ID
- 10.1073/pnas.1603455113
Entities
People
- Aaron R Goldman
- Ashish Kulkarni
- Navya Korimerla
- Poornima Rao
- Raghunath A. Mashelkar
- Shiladitya Sengupta
- Siva Natarajan
- Venkata S. Sabbisetti
- Vineethkrishna Chandrasekar
- Yashika Khater
Organizations
- American Cancer Society
- American Lung Association
- Congressionally Directed Medical Research Programs
- Dana–Farber Cancer Institute
- Harvard Medical School
- Harvard University
- National Cancer Institute
- National Chemical Laboratory